Burkitt-like lymphoma is an aggressive disease, but at the Israeli clinic Ichilov, thanks to years of accumulated experience and advanced technologies, the treatment of this pathology achieves high success rates even in complex cases. The most modern international protocols are applied here, and leading specialists continuously improve approaches based on global achievements. An individual therapy plan is built taking into account the characteristics of the tumour and the patient's condition, which allows for maximum effectiveness.
Treatment combines intensive chemotherapy, immunotherapy, and targeted drugs tailored to the individual. The conditions in the clinic are thoughtfully designed for a comfortable stay, and if necessary, personal accompaniment services for foreign patients are available. As a result, even with rapid disease progression, the chances of complete remission and long-term control remain high, instilling confidence in the right choice.
About the disease
Burkitt-like lymphoma is a highly malignant lymphoproliferative disease with aggressive dynamics. Despite its external similarity to the classical variant of Burkitt lymphoma, this pathology is classified as a separate category due to the absence of typical molecular-genetic markers, such as MYC rearrangement.
Three main clinical forms of Burkitt-like lymphoma are distinguished: sporadic, endemic, and associated with immunodeficiency states.
Causes
- HIV infection
- Epstein-Barr virus (EBV)
- Immunosuppression (transplantation, autoimmune diseases)
- Genetic disorders (rarely)
- Unknown factors in sporadic form
Symptoms
- Rapid enlargement of lymph nodes
- Abdominal pain, bloating
- Fever, night sweats
- Weight loss
- Weakness, fatigue
- Anemia, bleeding
- Intestinal obstruction
- Neurological disorders
Treatment methods
At Ichilov, the choice of treatment methods for Burkitt-like lymphoma is based on the results of immunohistochemical and molecular-genetic analyses, determining the exact subtype of the disease and the aggressiveness of the tumour, which allows for the formation of an intensive therapeutic strategy considering prognostic factors and risks of recurrence.
Intensive multi-component chemotherapy
From the moment of diagnosis of Burkitt-like lymphoma, immediate initiation of aggressive treatment is required due to the high rate of tumour cell division. Protocols include combinations of alkylating agents, antimetabolites, and topoisomerase inhibitors that act on various phases of the cell cycle. Chemotherapy cycles alternate with short intervals, not allowing the tumour to recover between courses. The intensity of the regimen requires constant monitoring of blood parameters and internal organ function, allowing for timely dose adjustments and prevention of critical complications.
Prevention of neuroleukemia
Considering the high tendency of Burkitt-like lymphoma to affect the central nervous system, even in the absence of clinical signs of involvement of the meninges, prophylactic administration of cytostatics begins. Intrathecal administration of drugs directly into the spinal canal through lumbar puncture creates therapeutic concentrations in the cerebrospinal fluid, where systemic drugs penetrate insufficiently due to the blood-brain barrier. The procedure is repeated several times according to the protocol, providing reliable protection of nervous tissue from metastasis, which is critical for preventing neurological complications and maintaining long-term prognosis.
Targeted immunotherapy
Molecular profiling of the tumour may reveal specific antigens on the surface of malignant B-lymphocytes, opening the possibility for the use of monoclonal antibodies. These biological agents selectively bind to tumour cells and initiate mechanisms for their destruction through complement activation or recruitment of natural killers. The addition of targeted agents to standard chemotherapy enhances the anti-tumour effect without a proportional increase in toxicity. At Ichilov, monitoring of effectiveness is conducted using PET-CT, allowing assessment of the metabolic activity of residual foci and adjustment of therapy at early stages in case of insufficient response.
High-dose consolidating chemotherapy
After achieving primary remission, the risk of recurrence remains significant due to the biological characteristics of Burkitt-like lymphoma, necessitating additional intensification of treatment. Consolidation cycles use increased doses of cytostatics to eliminate minimal residual disease, which may be the source of disease return. This stage is especially important for patients with adverse prognostic factors, such as high lactate dehydrogenase levels or massive tumour involvement at the time of diagnosis. Supportive therapy includes intensive hydration and medications to prevent tumor lysis syndrome, which occurs with massive cell death.
Autologous stem cell transplantation
In cases of particularly high risk or early relapse after the first line of therapy, the possibility of transplanting the patient's own hematopoietic stem cells is considered. They are collected from peripheral blood by apheresis during remission when the bone marrow is free of tumour cells. The patient then receives myeloablative chemotherapy in doses that completely destroy bone marrow hematopoiesis along with any possible residual lymphoma. The return of the patient's own stem cells allows for the restoration of the hematopoietic system, and the period after transplantation requires staying in a specialized department with monitoring of infection risks until complete engraftment of the transplant.
Radiation therapy to areas of massive involvement
When large tumour conglomerates of lymph nodes or extranodal foci are identified at the time of diagnosis, local irradiation of these areas may be prescribed after chemotherapy is completed. Modern IMRT technologies ensure precise delivery of the radiation dose to residual formations, minimizing the impact on surrounding healthy tissues. The decision on the necessity of radiation therapy is made individually based on the results of control imaging and assessment of metabolic activity in areas of primary involvement. This method enhances local control in anatomical areas where achieving complete remission with chemotherapy alone is complicated due to the size of the formations.
Supportive and accompanying therapy
The aggressiveness of treatment protocols for Burkitt-like lymphoma makes managing side effects an integral part of the therapeutic strategy at Ichilov. Granulocyte colony-stimulating factors reduce the duration of neutropenia and lower the risk of life-threatening infections, while modern antiemetic regimens ensure control of nausea even with highly emetogenic regimens. Prevention of tumor lysis syndrome includes forced diuresis, urine alkalinization, and the use of medications that break down uric acid. Nutritional support involving dietitians helps maintain body mass and metabolic status, which is critical for tolerating intensive courses and recovery speed between them.
CAR-T cell therapy
In cases of refractoriness to standard regimens or relapse after transplantation, innovative cell immunotherapy methods come into play. The patient's own T-lymphocytes are collected from the blood, genetically modified in a specialized laboratory by adding a chimeric antigen receptor that recognizes tumour cells. After a period of proliferation, the modified cells are returned to the patient, where they actively seek and destroy the lymphoma.
- Radiation therapy
- Bone marrow transplantation in Israel
- Chemotherapy
- CAR-T therapy
Diagnostic methods for the disease
Considering the high aggressiveness and progression rates of Burkitt-like lymphoma, conducting rapid and highly accurate diagnostics becomes the foundation of treatment, allowing for the adaptation of the therapeutic strategy to the specific characteristics of the neoplasm. At Ichilov, all studies are performed on high-precision modern equipment, and the entire diagnostic plan is formed in advance and carried out in a compressed timeframe.
First day
Upon arrival at the clinic, the patient immediately meets with the attending physician. The specialist collects a detailed medical history, conducts a thorough examination, assesses the condition of the lymph nodes, and prescribes a series of studies to obtain a complete picture of the disease.
Second day
On this day, all key diagnostic procedures are performed.
- Complete blood count with leukocyte formula
- Biochemical blood analysis
- Blood test for tumor markers (including LDH)
- Serological tests for HIV and EBV
- PCR diagnostics for Epstein-Barr virus
- Ultrasound of lymph nodes
- CT of the neck, chest, abdomen, and pelvis
- PET-CT
- Lymph node biopsy (fine-needle or open)
- Histological and immunohistochemical examination
- Cytogenetic analysis and FISH for MYC rearrangements
Third day
The attending physician gathers a consultation of specialists (oncologists, hematologists, pathomorphologists, radiologists), during which all results are discussed. This allows for the formulation of the most accurate and relevant individual treatment plan.
- Computed tomography
- Diagnostics — PET CT
- Ultrasound
- Biopsy and histological studies
- Blood biochemistry
How much does treatment in Israel cost
The final cost of treatment for Burkitt-like lymphoma is determined by the complexity of the diagnostic program, the type of intensive therapy used, and the necessity of using expensive biological agents. The price is significantly influenced by the volume of necessary laboratory tests and the total duration of hospitalization.
For a detailed cost estimate applicable to a specific case, please contact the consultant at the phone number provided on the website. The specialist will provide a preliminary estimate, explain the payment procedure, and assist in planning the organizational stages of the trip.
Advantages of treatment in Israel
- Recognized experts in the field of aggressive hematological pathologies by the global community
- Super-precise diagnostic technologies for rapid verification of rare tumour subtypes
- The most modern protocols for high-dose chemotherapy and innovative immunotherapy
- Personalized approach to developing a treatment strategy for each patient
- Maximally comfortable conditions for stay with accompaniment at all stages
Even before arriving at the clinic, it is possible to order a remote consultation with a leading specialist in video call format. Following the conversation, qualified recommendations, complete answers to medical questions, and detailed information on the application of the latest global technologies are provided.